Healthcare
Live Price
Offline$21.72
+3.87% today
1Y Change
-63.02%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PROCEPT BioRobotics Corporation (PRCT) is a Healthcare stock with a market cap of $1.40B and listed on NASDAQ. The stock last traded around $21.72 and down 63.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +37.2%, EPS growth of +1.7%, a dividend yield of 0.0%. What stands out right now is revenue +37.2%, EPS +1.7%, free cash flow +43.7% with operating margin -33.9% and ROIC -25.7%. Valuation sits in the middle of the pack at price/sales 4.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRCT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRCT Max Drawdown
-65.18%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRCT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$34.5M
-54.0% YoY
FY Net Income
-$59.9M
+31.3% YoY
Free Cash Flow
-$57.9M
+30.2% YoY
Revenue Growth
+37.2%
EPS Growth
+1.7%
Gross Margin
63.0%
Net Margin
-31.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 308M | 224M | 136M | 75M | 34M |
| Gross Profit | 196M | 137M | 71M | 37M | 16M |
| Operating Income | -104M | -97M | -109M | -81M | -54M |
| EBITDA | -80M | -82M | -98M | -79M | -51M |
| Net Income | -96M | -91M | -106M | -87M | -60M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 287M | 334M | 257M | 223M | 304M |
| Total Assets | 508M | 534M | 405M | 309M | 337M |
| Total Liabilities | 142M | 132M | 124M | 112M | 70M |
| Shareholder Equity | 366M | 402M | 281M | 197M | 267M |
| Total Debt | 52M | 80M | 79M | 77M | 54M |
| Net Debt | -235M | -253M | -178M | -145M | -250M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
57M
+28.7% YoY
Capital Expenditures
592K
+77.7% YoY
Free Cash Flow
58M
+30.2% YoY
Key ratios
Gross Margin
63.0%
Operating Margin
-33.9%
Net Margin
-31.8%
ROE
-27.7%
Debt / Equity
0.15x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.